BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy

计划入组 210 人 · 首次发布于 2026 年 8 月 10 日

BHB & CAR-T for Lymphomas

计划入组 5 人 · 首次发布于 2024 年 9 月 24 日

Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function

计划入组 24 人 · 首次发布于 2025 年 1 月 15 日

HRS-1893

ASP-1893

BL-1893

NATURECEUTICALS SDN. BHD.

Malaysia

BHR Pharma, LLC

United States

CRYOCORD SDN. BHD.

Malaysia

Braveheart Bio to Present at Cantor Global Healthcare Conference as It Advances BHB-1893 for Hypertrophic Cardiomyopathy

Braveheart Bio Raises $185M Series A to Advance Hypertrophic Cardiomyopathy Drug Licensed from Hengrui

Hengrui Pharma and Braveheart Bio Report Promising Phase 2 Results for Next-Generation Cardiac Myosin Inhibitor in Obstructive Hypertrophic Cardiomyopathy